<DOC>
	<DOCNO>NCT02183545</DOCNO>
	<brief_summary>The objective single rise dose study ( SRD ) investigate safety , tolerability , pharmacokinetics single rise dos BI 1060469 healthy Asian male subject .</brief_summary>
	<brief_title>Safety , Tolerability Pharmacokinetics Single Rising Oral Doses BI 1060469 Healthy Asian Male Volunteers</brief_title>
	<detailed_description />
	<criteria>Inclusion criterion : 1 . Healthy male base upon complete medical history , include physical examination , vital sign ( blood pressure , pulse rate ) , 12lead ECG , clinical laboratory test 2 . Chinese ethnicity , Japanese ethnicity accord follow criterion : Chinese ; bear China ethnic Chinese born outside China , descendent 4 ethnic Chinese grandparent born china Japanese ; bear Japan , live outside Japan &lt; 10 year , parent grandparent born Japan 3 . Age within range 18 45 year 4 . Body mass index within range 18.5 25 kg/m2 5 . Signed date write informed consent prior admission study accordance Good Clinical Practice ( GCP ) local legislation . Exclusion criterion : 1 . Any finding medical examination ( include blood pressure , pulse rate ECG ( electrocardiogram ) ) deviate normal judge clinically relevant investigator . Pulse rate outside range 5090 beat per minute blood pressure outside range 90140 systolic 5090 mmHg diastolic blood pressure confirm repeat measurement . 2 . Any laboratory value outside reference range investigator considers clinical relevance 3 . Serum creatinine laboratory value outside normal range 4 . Glomerular Filtration Rate accord CKDEPI ( Chronic Kidney Disease Epidemiology Collaboration ) Formula &lt; 60 ml/ min 5 . Current history relevant kidney , urinary tract disease abnormality ( i.e . nephrolithiasis , hydronephrosis , acute chronic nephritis , renal injury , renal failure , infection ) 6 . Gastrointestinal , hepatic , renal , respiratory , cardiovascular , metabolic , immunological hormonal disorder 7 . Surgery gastrointestinal tract could interfere kinetics study drug 8 . Diseases central nervous system ( epilepsy ) , central neurological disorder psychiatric disorder 9 . History relevant orthostatic hypotension , faint spell , blackouts 10 . Relevant chronic acute infection 11 . History relevant allergy/hypersensitivity ( include allergy trial medication excipients ) 12 . Intake drug long halflife ( great 24 hour ) within 30 day less 10 halflives respective drug prior study drug administration 13 . Intake NSAIDs ( Nonsteroidal antiinflammatory drug ) , COX2 ( Cyclooxygenase2 ) inhibitor , aspirin , ACE ( Angiotensin Converting Enzyme ) inhibitor , H2blockers OTC ( Over Counter Drug ) nutripharmaceuticals screen examination drug administration 14 . Use drug might reasonably influence result trial ( include renal function measurement ) might prolong QT/QTc interval within 14 day prior study drug administration 15 . Participation another trial investigational drug administration within 60 day prior administration trial medication 16 . Smoker ( 10 cigarette 3 cigar 3 pipes/day ) 17 . Inability refrain smoke specify trial day 18 . Alcohol abuse ( consumption 30 g/day ) 19 . Drug abuse positive drug screen 20 . Blood donation ( 100 mL within 30 day prior administration trial medication intend trial ) 21 . Intention perform excessive physical activity within one week prior administration trial medication trial 22 . Inability comply dietary regimen trial site 23 . A marked baseline prolongation QT/QTc interval ( repeat demonstration QTc interval great 450 m ) relevant ECG find 24 . A history additional risk factor Torsades de Pointes ( heart failure , hypokalemia , family history Long QT Syndrome ) 25 . Subject assessed investigator unsuitable inclusion , instance , consider able understand comply study requirement , condition would allow safe participation study</criteria>
	<gender>Male</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>45 Years</maximum_age>
	<verification_date>October 2014</verification_date>
</DOC>